MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jfma.2019.10.003

Медицинская библиотека · Journal of the Formosan Medical Association = Taiwan yi zhi · 2019

Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients.

Hsu Shih-Jer, Enkhzaya Sukhee, Lin You-Yu, Tseng Tai-Chung, Khosbayar Tulgaa, Tsai Cheng-Hsueh, Wang Tzu-San, Enkhtuya Damba, Ivshinkhorol Dogsom, Naranzul Nyamsuren, Jargalsaikhan Badarch, Amarsanaa Jazag, Baatarkhuu Oidov, Kao Jia-Horng

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Mongolia has the highest prevalence of hepatitis C virus (HCV) infection worldwide. Ledipasvir/sofosbuvir (LDV/SOF) was introduced to Mongolia since 2016 for HCV eradication. It has been reported that HCV resistance-associated substitutions (RASs) would affect the effectiveness of LDV/SOF in western chronic hepatitis C (CHC) patients. We thus investigated the effectiveness of LDV/SOF and the impact of RAS on the treatment outcome in Mongolian CHC patients.

METHODS

Patients with genotype (GT) 1b HCV infection were prospectively enrolled in Mongolia and treated with LDV/SOF for 12 weeks. The proportion of pre-treatment NS5A Y93H RAS in viral quasispecies was measured with next-generation sequencing. The endpoint of LDV/SOF effectiveness was sustained virological response at post-treatment week 12 (SVR12).

RESULTS

A total of 94 CHC patients were evaluated. The baseline Y93H proportion was <1% in 74 patients, 1-15% in 7, 15-50% in 2, and ≥50% in 11. All patients completed 12-week LDV/SOF treatment and the SVR rate was 90.4%. The rate of failure to achieve SVR12 for patients with Y93H < 1%, 1-15%, and ≥15% were 0%, 14.3%, and 61.5%, respectively (p for trend = 0.001). In univariable analysis, older age, baseline alanine transaminase level <40 U/mL, and a higher proportion of Y93H were associated with treatment failure. In multivariable analysis, only a higher proportion of Y93H was associated with treatment failure (p = 0.022).

CONCLUSION

LDV/SOF therapy achieves a high SVR rate in Mongolian CHC GT1b patients without baseline Y93H RAS. A higher proportion of Y93H may severely undermine the effectiveness of LDV/SOF.

Для цитирования: Hsu Shih-Jer, Enkhzaya Sukhee, Lin You-Yu, Tseng Tai-Chung, Khosbayar Tulgaa, Tsai Cheng-Hsueh, Wang Tzu-San, Enkhtuya Damba, Ivshinkhorol Dogsom, Naranzul Nyamsuren, Jargalsaikhan Badarch, Amarsanaa Jazag, Baatarkhuu Oidov, Kao Jia-Horng. Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients.. Journal of the Formosan Medical Association = Taiwan yi zhi. 2019. DOI: 10.1016/j.jfma.2019.10.003.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.